Acute Myeloid Leukemia Stem Cells and CD33-targeted Immunotherapy

Blood - United States
doi 10.1182/blood-2011-11-325050
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Hematology

Related search

Preliminary Results of the Safety of Immunotherapy With Gemtuzumab Ozogamicin Following Reduced Intensity Allogeneic Stem Cell Transplant in Children With CD33+ Acute Myeloid Leukemia

Clinical Cancer Research
Cancer ResearchOncology
2005English

Recent Developments in Immunotherapy of Acute Myeloid Leukemia

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2017English

In Vitro and in Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia

Molecular Cancer Therapeutics
Cancer ResearchOncology
2016English

Distribution and Levels of Cell Surface Expression of CD33 and CD123 in Acute Myeloid Leukemia

Blood Cancer Journal
OncologyHematology
2014English

Targeted Therapy in Acute Myeloid Leukemia: Aim With Caution

International Journal of Hematologic Oncology
OncologyHematologyPharmacology
2012English

Cytomegalovirus Serostatus Affects Autoreactive NK Cells and Outcomes of IL2-based Immunotherapy in Acute Myeloid Leukemia

Cancer immunology research
Cancer ResearchImmunology
2018English

Identifying Leukemia-Specific Neoepitopes From Next-Generation Sequencing Data to Develop Targeted Immunotherapy for Pediatric Acute Myeloid Leukemiaig

Biology of Blood and Marrow Transplantation
TransplantationHematology
2016English

SHIP1 Is Targeted by miR-155 in Acute Myeloid Leukemia

Oncology Reports
MedicineCancer ResearchOncology
2014English

Acute Myeloid Leukemia

JAMA - Journal of the American Medical Association
Medicine
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy